5-chloro-N-(2-chloro-5-cyanophenyl)-2-hydroxybenzamide | 1401460-87-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-N-(2-chloro-5-cyanophenyl)-2-hydroxybenzamide
• CAS: 1401460-87-4
• 化学式: C₁₄H₈Cl₂N₂O₂
• 分子量: 307.136
• InChiKey: QFIVIYJFMCHNKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-氯代水杨酸 、 3-氨基-4-氯苯腈 在 三氯化磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 1.5h， 生成 5-chloro-N-(2-chloro-5-cyanophenyl)-2-hydroxybenzamide
  参考文献：
  名称：

  Salicylanilide Inhibitors of Toxoplasma gondii

  摘要：

  Toxoplasma gondii (T. gondii) is an apicomplexan parasite that can cause eye disease, brain disease, and death, especially in congenitally infected and immune-compromised people. Novel medicines effective against both active and latent forms of the parasite are greatly needed. The current study focused on the discovery of such medicines by exploring a family of potential inhibitors whose antiapicomplexan activity has not been previously reported. Initial screening efforts revealed that niclosamide, a drug approved for anthelmintic use, possessed promising activity in vitro against T. gondii. This observation inspired the evaluation of the activity of a series of salicylanilides and derivatives. Several inhibitors with activities in the nanomolar range with no appreciable in vitro toxicity to human cells were identified. An initial structure activity relationship was explored. Four compounds were selected for evaluation in an in vivo model of infection, and two derivatives with potentially enhanced pharmacological parameters demonstrated the best activity profiles.

  DOI：

  10.1021/jm3007596

文献信息

• Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals
  申请人：Wood Richard Delarey

  公开号：US20130324555A1

  公开（公告）日：2013-12-05

  The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.

  本发明涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物，单独使用或与一个或多个其他活性或辅料药物物质结合使用。本发明进一步涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物的组合。本发明进一步涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物的组合，进一步包含一个或多个活性或辅料药物物质。
• Salicylanilide Inhibitors of Toxoplasma gondii
  作者：Alina Fomovska、Richard D. Wood、Ernest Mui、Jitenter P. Dubey、Leandra R. Ferreira、Mark R. Hickman、Patricia J. Lee、Susan E. Leed、Jennifer M. Auschwitz、William J. Welsh、Caroline Sommerville、Stuart Woods、Craig Roberts、Rima McLeod

  DOI：10.1021/jm3007596

  日期：2012.10.11

  Toxoplasma gondii (T. gondii) is an apicomplexan parasite that can cause eye disease, brain disease, and death, especially in congenitally infected and immune-compromised people. Novel medicines effective against both active and latent forms of the parasite are greatly needed. The current study focused on the discovery of such medicines by exploring a family of potential inhibitors whose antiapicomplexan activity has not been previously reported. Initial screening efforts revealed that niclosamide, a drug approved for anthelmintic use, possessed promising activity in vitro against T. gondii. This observation inspired the evaluation of the activity of a series of salicylanilides and derivatives. Several inhibitors with activities in the nanomolar range with no appreciable in vitro toxicity to human cells were identified. An initial structure activity relationship was explored. Four compounds were selected for evaluation in an in vivo model of infection, and two derivatives with potentially enhanced pharmacological parameters demonstrated the best activity profiles.